Dixon Giles, Hague Samuel, Mulholland Sarah, Adamali Huzaifa, Khin Aye Myat Noe, Thould Hannah, Connon Roisin, Minnis Paul, Murtagh Eoin, Khan Fasihul, Toor Sameen, Lawrence Alexandra, Naqvi Marium, West Alex, Coker Robina K, Ward Katie, Yazbeck Leda, Hart Simon, Garfoot Theresa, Newman Kate, Rivera-Ortega Pilar, Stranks Lachlan, Beirne Paul, Bradley Jessica, Rowan Catherine, Agnew Sarah, Ahmad Mahin, Spencer Lisa G, Aigbirior Joshua, Fahim Ahmed, Wilson Andrew M, Butcher Elizabeth, Chong Sy Giin, Saini Gauri, Zulfikar Sabrina, Chua Felix, George Peter M, Kokosi Maria, Kouranos Vasileios, Molyneaux Philip, Renzoni Elisabetta, Vitri Benedetta, Wells Athol U, Nicol Lisa M, Bianchi Stephen, Kular Raman, Liu HuaJian, John Alexander, Barth Sarah, Wickremasinghe Melissa, Forrest Ian A, Grimes Ian, Simpson A John, Fletcher Sophie V, Jones Mark G, Kinsella Emma, Naftel Jennifer, Wood Nicola, Chalmers Jodie, Crawshaw Anjali, Crowley Louise E, Dosanjh Davinder, Huntley Christopher C, Walters Gareth I, Gatheral Timothy, Plum Catherine, Bikmalla Shiva, Muthusami Raja, Stone Helen, Rodrigues Jonathan C L, Tsaneva-Atanasova Krasimira, Scotton Chris J, Gibbons Michael A, Barratt Shaney L
Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK.
South West Peninsula ILD Network, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
ERJ Open Res. 2024 Jan 15;10(1). doi: 10.1183/23120541.00529-2023. eCollection 2024 Jan.
Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting.
26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability were collected electronic survey.
24 UK prescribing centres responded to the service evaluation invitation. Between 17 November 2021 and 30 September 2022, 1120 patients received a multidisciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298 out of 1120, 26.6%), connective tissue disease associated ILD (197 out of 1120, 17.6%), rheumatoid arthritis associated ILD (180 out of 1120, 16.0%), idiopathic nonspecific interstitial pneumonia (125 out of 1120, 11.1%) and unclassifiable ILD (100 out of 1120, 8.9%). Of these, 54.4% (609 out of 1120) were receiving concomitant corticosteroids, 355 (31.7%) out of 1120 were receiving concomitant mycophenolate mofetil and 340 (30.3%) out of 1120 were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD.
We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting.
尼达尼布可减缓进行性纤维化（PF）间质性肺疾病（ILD）患者肺功能下降的进展，并于2021年6月在苏格兰的英国国家医疗服务体系（NHS）以及2021年11月在英格兰、威尔士和北爱尔兰被推荐用于该适应症。迄今为止，尚未在真实世界环境中对尼达尼布用于PF-ILD进行全国性评估。
2021年11月17日至2022年9月30日期间，邀请了英国的26个中心参与一项全国性服务评估。通过电子调查收集了有关基础诊断、肺功能测试、诊断标准、影像学表现、同时进行的免疫抑制治疗和药物耐受性的汇总数据。
24个英国处方中心回复了服务评估邀请。在2021年11月17日至2022年9月30日期间，1120例患者接受了多学科团队的建议，开始使用尼达尼布治疗PF-ILD。最常见的基础诊断为过敏性肺炎（1120例中的298例，26.6%）、结缔组织病相关ILD（1120例中的197例，17.6%）、类风湿关节炎相关ILD（1120例中的180例，16.0%）、特发性非特异性间质性肺炎（1120例中的125例，11.1%）和无法分类的ILD（1120例中的100例，8.9%）。其中，54.4%（1120例中的609例）正在接受糖皮质激素联合治疗，1120例中的355例（31.7%）正在接受霉酚酸酯联合治疗，1120例中的340例（30.3%）正在接受另一种免疫抑制/调节治疗。ILD的影像学进展伴呼吸症状恶化是诊断PF-ILD最常见的原因。
我们证明了尼达尼布在广泛的基础疾病中用于治疗PF-ILD的情况。尼达尼布经常与免疫抑制和免疫调节治疗联合使用。在真实世界环境中，尼达尼布用于治疗PF-ILD已显示出可接受的耐受性。
Zotero 插件
